Imatinib has revolutionized the treatment of gastrointestinal stromal tumors (GIST); however, primary and secondary resistance to imatinib is still a major cause of treatment failure. Multiple mechanisms are involved in this progression. In the present study, we reported a novel mechanism for the acquired resistance to imatinib, which was induced by enhanced Ca 2+ influx via stromal-interacting molecule 1 (STIM1)-mediated store-operated Ca 2+ entry (SOCE). We found that the STIM1 expression level was related to the acquired resistance to imatinib in our studied cohort. The 
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knockdown suppressed the proliferation of imatinib-resistant GIST cell lines and xenografts. In addition, STIM1-mediated SOCE exerted an antiapoptotic effect via the MEK/ERK pathway. The results from this study provide a basis for further research into potential novel therapeutic strategies in acquired imatinib-resistant GIST.
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| INTRODUCTION
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the digestive tract. The incidence of GIST and so-called subclinical GIST is nearly 10%-30% in adults. [1] [2] [3] KIT and PDGFRA mutations are recognized as the driving factors of GIST, 4, 5 with the decisive therapy being selective receptor tyrosine kinase Oncology, and Asian consensus . [6] [7] [8] Although more than 80% of patients benefit from imatinib monotherapy, half still develop acquired resistance within 2 years of treatment, leading to recurrence or metastasis, and increasing mortality and morbidity. 9 Intersti- - showed that SOCE participates in resistance to cisplatin. 18 However, the mechanism by which SOCE promotes the malignancy of tumor cells remains inconclusive and the role of STIM1-mediated SOCE in GIST is unclear.
In this study, we investigated the correlation between the STIM1 expression level and imatinib resistance in GIST patients. We found that STIM1 was upregulated in imatinib-resistant GIST cells compared to sensitive parental cells, and knockdown or overexpression of STIM1 has significant effects on SOCE, proliferation and drug response in imatinib-resistant GIST cells. We further revealed that STIM1-mediated SOCE could induce apoptosis via the MEK/ERK pathway.
| MATERIALS AND METHODS

| Patients and specimens
A total of 35 specimens were collected from pathologically-con- 
| Cell culture
Human GIST cell lines GIST-T1 and GIST-882 were obtained from the Shanghai Cancer Institute. Both cell lines were grown in DMEM (Gibco, Gaithersburg, MD, USA) that contained 10% FBS (Gibco).
Cells were cultured at 37°C in 5% CO 2 and at 95% relative humidity.
Imatinib-resistant sublines emerged from cell cultures with gradually increasing doses of imatinib. Imatinib-sensitive cell lines GIST-882
and GIST-T1 were cultured in medium with gradually increasing doses of imatinib (.2, .4 and 1 μmol/L) and were obtained after 1, 2 and 4 months, respectively. Relative resistance assessment was applied to detect the stability of the resistant phenotype originating from each culture continuously in medium with increasing concentrations of imatinib for up to 6 months. Imatinib (STI571) was purchased from Selleck (Shanghai, China).
| Quantitative RT-PCR
Total RNA was isolated from tissue samples or cultured cells using TRIzol Reagent (Takara, Shiga, Japan). cDNA was synthesized with PrimeScript Reverse Transcriptase (Takara, Osaka, Japan) following the manufacturer's instructions. Real-time PCR was performed with the StepOne Real-Time PCR System (Applied Biosystems, Foster City, USA) with SYBR Green (Takara, Dalian, China). GAPDH was used as the internal standard. Primer sequences used for amplification were listed in supporting information (Supplementary Table S1 ).
| Western blotting
Protein was extracted using radioimmunoprecipitation assay buffer (Cell Signaling, Danvers, MA, USA). A total of 25 μg of protein was loaded onto a 12% sodium dodecyl sulfate polyacrylamide 
| Cell viability assays
The Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) assay was used for the assessment of cell viability. Cells were plated at 2 × 10 3 cells per well in 96-well plates. For proliferation assays, absorbance at 450 nm was measured for 5 days. To determine the half maximal inhibitory concentration (IC 50 ), cells were rinsed the next day and cultured with various doses of imatinib for 48 hours. Colony formation assays were performed to assess anchorage-independent growth. A total of 500 cells were seeded in 6-well plates and cultured for 10 days. Then, the cells were fixed, stained and photographed. T Figure 1A,B) . Based on the fold change, we divided patients into a high-level group (fold change ≥ 2) and a low-level group (fold change <2). Further clinicopathological association examination of the 35 GIST patients showed that STIM1 was significantly associated with acquired imatinib resistance (P = .022) ( Table 1 ). STIM1 expression levels in GIST patients who developed imatinib resistance were significantly higher than in those who did not develop imatinib resistance (P < .01) ( Figure 1C ). Furthermore, western blotting confirmed that STIM1 protein expression levels in GIST tissues were higher than those in the corresponding non-GIST tissues ( Figure 1D ). | 2795 peak of the Ca 2+ elevation and found that SOCE was higher in imatinib-resistant cells than that in imatinib-sensitive cells (Figure 2A,B) .
| Calcium imaging
| Xenograft nude mouse model
A B L E 1 Association of STIM1 expression with the clinicopathological characteristics of GIST
STIM1, Orai1 and TRPC channel expression in imatinib-resistant cells
and their parental counterparts were compared using qRT-PCR (Supplementary Figure S1 ); only the STIM1 expression level had significant change. Among the 4 cell lines, STIM1 expression decreased in imatinib-sensitive GIST-882 and GIST-T1 cells, whereas it was overexpressed in the homologous imatinib-resistant cells ( Figure 2C ).
Consistent protein levels were observed in western blotting (Figure 2D ).
| Knockdown of stromal-interacting molecule 1-suppressed proliferation of imatinib-resistant gastrointestinal stromal tumor cells in vitro
We transfected GIST-882-R and GIST-T1-R cell lines with 3 different siRNA against STIM1. The efficiency of each siRNA was assessed by qRT-PCR and, from this, the third siRNA was employed ( Figure 3A) . Western blot analysis confirmed the knockdown efficiency ( Figure 3B ). We used CCK-8 and colony formation assays to explore the influence of STIM1 knockdown on GIST cell proliferation. Figure 3C shows that the viability of GIST-882-R and GIST-T1-R cells were markedly inhibited by STIM1 depletion (P < .05). In addition, compared with the si-NC (negative control) groups, the downregulation of STIM1 reduced the capacity of colony formation in GIST-882-R and GIST-T1-R cells (Figure 3D ). 13.42%, respectively (P < .05; Figure 6A ). Considering that the deregulation of MEK/ERK phosphorylation represents an important antiapoptotic mechanism in various tumors, 19 we studied the phosphorylation status of proteins involved in the above signaling pathway using western blotting. We found that p-MEK and p-ERK expression levels decreased significantly when STIM1 was silenced ( Figure 6B ). These results indicated that the MEK/ERK pathway might be regulated by the STIM1-mediated SOCE in imatinib-resistant GIST cells.
| DISCUSSION
Imatinib has revolutionized the treatment of GIST; however, primary and secondary resistance to imatinib is still a major cause of treatment failure. Several mechanisms have been found to be responsible for imatinib resistance, including secondary point mutations, gene amplification, autophagy and apoptosis, and other mechanisms. These mechanisms are complex, often heterogeneous, and not fully understood. 20 Among all possible reasons, second point mutations in the kinase or loop domain of KIT or PDGFRA are considered the main cause. 21 However, more than a few imatinib-resistant GIST do not detect such mutations, 22, 23 Difference in sample size and detecting methods may explain these discrepancies. The present study examined STIM1 expression in both translational and post-translational levels and matched it to the clinicopathological characteristics of GIST patients. We failed to find correlation between STIM1 and risk stratification (Table 1) ; however, we found that STIM1 was related to acquired imatinib resistance in the studied cohort. Therefore, we investigated the function of STIM1-mediated SOCE in imatinib-resistant GIST.
Based on our data, we suggest that the antiapoptotic effect induced by SOCE is one of the mechanisms leading to imatinib resistance. Apoptosis has been widely investigated in GIST and is closely related to tumor progression. Wang et al 29 found a significant negative correlation between apoptosis and the degree of GIST differentiation. Moreover, apoptosis is also involved in imatinib response. Liu et al 30 report that GIST cells survived imatinib treatment by escaping from apoptosis. Another study reports that apoptosis induced by miR-518a-5p affected the cellular response to the drug, causing imatinib resistance in GIST. 31 We have also found previously that STIM1-mediated SOCE contributes to apoptosis via phosphorylation of the MEK/ERK pathway, which is a classical signaling pathway that participates in cell growth, EMT and apotosis. 
